ReNeuron raises $7.3M

The U.K.'s ReNeuron Group has raised £4.7 million ($7.3 million), before expenses, from existing and new institutional investors. The money will support the company for the next 12 months and be directed towards the Phase I trial of the company's ReN001 stem cell therapy for disabled stroke patients. It will also fund late pre-clinical testing of the company's ReN009 therapy for peripheral arterial disease. ReNeuron release

Suggested Articles

Shorla Pharma picked up $8.3 million to push its cancer programs through U.S. regulatory approval and gear up for its first drug launch in 2021.

Genor Biopharma banked $160 million from the likes of Hillhouse and Temasek Holdings to advance its clinical-stage autoimmune and cancer programs.

Going from being the CSO of Bristol Myers Squibb to running one of the biggest cancer research organizations in the world is a major career shift.